

Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala

***Dr. Murtaza Khorakiwala is Managing Director
Huzaifa Khorakiwala is Executive Director***

Mumbai, April 1, 2009

The Board of Directors of Pharmaceutical and biotechnology major Wockhardt Limited announced the company's succession plan under the continued leadership of Chairman Habil Khorakiwala by appointing Dr. Murtaza Khorakiwala as the Managing Director and Huzaifa Khorakiwala as Executive Director.

"This decision was taken to develop a long-term succession plan in the best interest of the company and all its stakeholders," said Wockhardt Chairman Habil Khorakiwala. "This will give me an opportunity to mentor and develop the next generation leaders whilst I am fully involved in providing leadership, strategic vision and direction to the company's business operations," he further added.

Dr. Murtaza Khorakiwala joined Wockhardt in 2000 and has worked in various capacities in the company. He has a degree in Medicine from India and Management Education in the USA. He has worked in our subsidiary in the UK for 3 years and has been fully involved in the biotechnology business, manufacturing and the Negma operations in France. He is also a key member of Wockhardt's Global Strategic Planning Team.

Huzaifa Khorakiwala is a Commerce graduate from India and has done his Management education at the Yale University, USA. Over the years he has been handling various Wockhardt businesses like Animal Health, International Business and Corporate Administration. Additionally, he devotes significant part of his time to Wockhardt's Corporate Social Responsibility and heads the Wockhardt Foundation as its Chief Executive Officer.

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 15 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland, France and Germany with a multi-ethnic workforce from 14 different nationalities.